Clinical Trial Update: A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating niraparib in BAP1- and DDR-deficient neoplasms including mesothelioma and uveal melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Mesothelioma
• Renal Cell Carcinoma
• Uveal Melanoma

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: University of Florida | Conditions: Mesothelioma, Uveal Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2023-09-15